The Bicyclo Ring System Consists Of The Five-membered Hetero Ring And A Benzene Ring (e.g., Indole, Etc.) Patents (Class 514/415)
  • Patent number: 10377710
    Abstract: The present invention relates to a novel, improved, commercially viable and industrially advantageous process for the preparation of Silodosin of Formula (I), its pharmaceutically acceptable salts or solvates thereof. The invention relates to the preparation of considerably pure Silodosin with high yield.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: August 13, 2019
    Assignee: MANKIND PHARMA LTD.
    Inventors: Kuldeep Singh Gangwar, Anil Kumar, Bhuwan Bhashkar
  • Patent number: 10369310
    Abstract: Disclosed is an apparatus for treating a respiratory disorder. The apparatus comprises a pressure device, and a controller, including at least one processor, configured to control the pressure device to: supply, upon initiation of treatment, a flow of pressurized air to the airway of a patient at a treatment pressure according to a pre-sleep profile of pressure versus time, increase, upon detection of sleep onset of the patient, the treatment pressure to a predetermined therapeutic pressure according to a bridging profile of pressure versus time, and supply the flow of pressurized air to the airway of the patient at a therapeutic pressure.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: August 6, 2019
    Assignee: ResMed Pty Ltd
    Inventors: Dinesh Ramanan, Jeffrey Peter Armitstead, Joon-Pil Hwang, Jane Zona Mchenry, Nathan John Row
  • Patent number: 10273246
    Abstract: In one aspect, the invention relates to substituted 5H-[1,2,5]oxadiazolo [3?,4?:5,6]pyrazino[2,3-b]indole analogs, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and A methods of treating disorders, e.g., various tumors and cancers, associated with a ?-catenin/T-cell factor interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: April 30, 2019
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Haitao Ji, Yongqiang Zhang, Min Zhang, Jonathan L. Catrow
  • Patent number: 10220024
    Abstract: An object of the present invention is to provide a cancer cell inhibitory drug, particularly a cancer stem-cell inhibitory drug, or a cancer stem-cell detection probe. A cancer cell inhibitory drug containing at least a compound represented by general formula (1).
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: March 5, 2019
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Taichi Shintou, Tsuyoshi Nomoto, Kohei Watanabe, Takeshi Miyazaki, Toshio Tanaka, Yasuhito Shimada, Yuhei Nishimura
  • Patent number: 10206902
    Abstract: The present invention concerns mono- or di-substituted indole compounds of formula (I) which are useful to prevent or treat dengue viral infections and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: February 19, 2019
    Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
  • Patent number: 10194918
    Abstract: The invention provides methods for reducing traumatic injury through the use of ischemic conditioning.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: February 5, 2019
    Assignee: The Hospital for Sick Children
    Inventor: Christopher Caldarone
  • Patent number: 10039703
    Abstract: The invention relates to a composition comprising 0.01% to 15% resveratrol and 0.01% to 15% of melatonin. In a preferred embodiment, the composition comprises 5% resveratrol and 0.1% melatonin. The invention also relates to the use of the said composition to reduce hair loss and/or increase regrowth of hair in a human subject.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: August 7, 2018
    Assignee: Triple Hair Inc.
    Inventor: Houfar Sekhavat
  • Patent number: 10034857
    Abstract: The invention provides stable, spray-dried, particle formulations containing a triptan, preferably sumatriptan, or a pharmaceutically acceptable salt thereof, which are useful for pulmonary administration to the respiratory tract of a patient for the treatment of disease.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: July 31, 2018
    Assignee: Civitas Therapeutics, Inc.
    Inventor: Michael M. Lipp
  • Patent number: 10034858
    Abstract: The present invention relates to a pharmaceutical composition for topical administration comprising a compound of formula I, 3-{4-[2-{5-chloro-1-(diphenylmethyl)-2-[2-({[2-(trifluoromethyl)benzyl]sulfonyl}amino)ethyl]-1H-indol-3-yl}ethyl]sulfonyl}phenyl}propanoic acid: or pharmaceutically acceptable salts thereof; and to methods of treating inflammation comprising topical administration of a compositions comprising a compound of formula I.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: July 31, 2018
    Assignee: Ziarco Pharma Ltd.
    Inventors: Wai Leung Liu, Lynn Purkins, Michael Yeadon
  • Patent number: 9951019
    Abstract: The invention provides compounds of formula (I): wherein, A, C, D, X, and Y have any of the values defined in the specification, and salts thereof. The compounds are SIRT2 inhibitors and are useful for treating SIRT2 associated conditions.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: April 24, 2018
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Liqiang Chen, Teng Ai, Swati More
  • Patent number: 9920093
    Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: March 20, 2018
    Assignee: TetraLogic Birinapant UK Ltd.
    Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
  • Patent number: 9907841
    Abstract: Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such as botulinum neurotoxin, to the patient, are provided.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: March 6, 2018
    Assignee: Allergan, Inc.
    Inventors: Ivan Aguilar, Gustavo M. Gaxiola, Gilberto P. Paz
  • Patent number: 9902694
    Abstract: This invention relates to crystalline forms of (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile, a modulator of the androgen receptor, and methods for the use in treatment.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: February 27, 2018
    Assignee: GlaxoSmithKline Intellectual Property (No 2) Limited
    Inventors: Istvan Kaldor, Dalin Tang
  • Patent number: 9889126
    Abstract: Described herein is a method of using a topical, pharmaceutical composition, particularly a dermatological composition, comprising naratriptan to treat rosacea and in particular erythematotelangiectatic rosacea.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: February 13, 2018
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Michel Rivier, Isabelle Carlavan, Jerome Aubert
  • Patent number: 9850262
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: December 26, 2017
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein
  • Patent number: 9840464
    Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: December 12, 2017
    Assignee: TetraLogic Birinapant UK Ltd.
    Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
  • Patent number: 9834514
    Abstract: The present disclosure describes a method to treat conditions, including bacterial infections and cancer, using a photosensitive compound that, upon exposure to white light, can be activated. The photosensitive compound can also interact synergistically with antibiotics used concomitantly to kill drug-resistant bacteria. The photosensitive compounds can also be used to inhibit the proliferation of cancer cells.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: December 5, 2017
    Assignee: NEW MEXICO TECH RESEARCH FOUNDATION
    Inventors: Snezna Rogelj, Liliya Frolova, Alexander Kornienko, Leslie D. Edwards, Cody Champion, Kailee Zingler, Danielle Nicole Turner
  • Patent number: 9763916
    Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: September 19, 2017
    Assignee: ARCA Biopharma, Inc.
    Inventors: Michael R. Bristow, Jonathan D. Port
  • Patent number: 9758481
    Abstract: Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: September 12, 2017
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Jeffrey A. Toretsky, Aykut Uren, Milton Lang Brown, Yali Kong
  • Patent number: 9725452
    Abstract: The present invention relates to heterocyclic compounds (e.g., compounds described by Formula (I)) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role. The heterocyclic compounds described herein can also achieve improved activity and selectivity towards RIP1 and/or RIP3.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 8, 2017
    Assignees: Presidents and Fellows of Harvard College, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Tufts University, University of Houston
    Inventors: Junying Yuan, Alexei Degterev, Gregory D. Cuny
  • Patent number: 9693995
    Abstract: The present invention relates to a pharmaceutical composition for topical administration comprising a compound of formula I, 3-{4-[2-{5-chloro-1-(diphenylmethyl)-2-[2-({[2-(trifluoromethyl)benzyl]sulfonyl}amino)ethyl]-1H-indol-3-yl}ethyl]sulfonyl}phenyl}propanoic acid: or pharmaceutically acceptable salts thereof; and to methods of treating inflammation comprising topical administration of a compositions comprising a compound of formula I.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: July 4, 2017
    Assignee: Ziarco Pharma Limited
    Inventors: Wai Leung Liu, Lynn Purkins, Michael Yeadon
  • Patent number: 9670149
    Abstract: A process for preparing guanidino-functional, free radically polymerizable compounds comprises (a) combining (1) an amine compound comprising (i) at least one primary aliphatic amino group and (ii) at least one secondary aliphatic amino group, primary aromatic amino group, or secondary aromatic amino group, and (2) a guanylating agent; (b) allowing or inducing reaction of the amine compound and the guanylating agent to form a guanylated amine compound; (c) combining (1) the guanylated amine compound, and (2) a reactive monomer comprising (i) at least one ethylenically unsaturated group and (ii) at least one group that is reactive with an amino group; and (d) allowing or inducing reaction of the guanylated amine compound and the reactive monomer to form a guanidino-functional, free radically polymerizable compound.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: June 6, 2017
    Assignee: 3M Innovative Properties Company
    Inventors: Jerald K. Rasmussen, George W. Griesgraber, James I. Hembre
  • Patent number: 9669006
    Abstract: A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of hot flashes in a female subject, such as experiencing symptoms of perimenopause. The composition includes a phytoestrogen and lycopene in an oral dosage form. The phytoestrogen may include a plant lignan including at least one of Matairesinol, 7-hydroxymatairesinol, Secoisolariciresinol, Lariciresinol and Pinoresinol. The lycopene may include a lycopene complex having at least one of phytoene, phytofluene, beta-carotene, tocopherols and phytosterols.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: June 6, 2017
    Assignee: U.S. NUTRACEUTICALS, LLC
    Inventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck, Jessica Engle
  • Patent number: 9649294
    Abstract: Glucagon receptor antagonist compounds are disclosed which are of long duration of action. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: May 16, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Libo Xu, Emma R. Parmee, Xibin Liao
  • Patent number: 9603836
    Abstract: The present invention relates to compound of Formula I or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula I as IDO1 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer and endometriosis. The invention also relates to a process for manufacturing compounds of Formula I.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: March 28, 2017
    Assignee: ITEOS THERAPEUTICS
    Inventors: Stefano Crosignani, Sandra Cauwenberghs, Gregory Driessens, Frederik Deroose
  • Patent number: 9554883
    Abstract: The present artificial insemination instrument may include a single use, hollow, elongate, metal pipette and a single disposable syringe that is not toxic to bovine sperm. The apparatus is used with any type of diluent that is not toxic to bovine sperm. In various embodiments, a technician may use non-sorted reduced sperm count semen straws from a bull stud, cut an unsorted semen straw into several pieces to use one piece at a time per cow, thaw one straw and mix the non-sorted semen with diluent, or use reduced sperm count semen straws filled with sex sorted semen by the manufacturer. A procedure is disclosed to use the artificial insemination instrument, reduced sperm count semen from any of the aforementioned sources, a non-toxic syringe, and a diluent to achieve conception rates at least as good as conventional prior art device and procedure conception rates.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: January 31, 2017
    Inventor: Brad K. Stroud
  • Patent number: 9511050
    Abstract: Methods and compositions provided herein relate to the treatment of cancer. In some embodiments, the compositions have utility in the treatment of cancers including glioblastoma multiforme and lung cancer.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: December 6, 2016
    Assignee: Georgetown University
    Inventors: Jeffrey A. Toretsky, Aykut Uren
  • Patent number: 9505775
    Abstract: Compounds of Formula (I) wherein R1, R2, R3A, R3B, Y, Z1 and Z2 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: November 29, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carl Thibeault, Jean Rancourt, Pierre L. Beaulieu, Anne Décor, Chantal Grand-Maitre, Cyrille Kuhn, Elisia Villemure, Oliver Hucke, Simon Surprenant, Melissa Leblanc, Jean-Eric Lacoste, Benoit Moreau, Eric Jolicoeur
  • Patent number: 9499484
    Abstract: The invention provides indole and indoline derivatives and slats thereof, compositions comprising them and uses thereof for the treatment of diseases and disorders.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: November 22, 2016
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
    Inventors: Abraham Nudelman, Marta Weinstock-Rosin
  • Patent number: 9474730
    Abstract: Methods and compositions that can be used to identify and characterize inhibitors of K-ras localization to the plasma membrane and in doing so inhibit the signal transduction of K-ras. Such compositions can be used to treat K-ras mediated disorders, such as cancer.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: October 25, 2016
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: John F. Hancock, Dharini Van Der Hoeven, Kwang-Jin Cho
  • Patent number: 9446023
    Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: September 20, 2016
    Assignee: ARCA Biopharma, Inc.
    Inventors: Michael R. Bristow, Jonathan D. Port
  • Patent number: 9434687
    Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: September 6, 2016
    Assignee: Randox Laboratories Limited
    Inventors: Elouard Benchikh, Stephen Peter FitzGerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
  • Patent number: 9394249
    Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: July 19, 2016
    Assignee: TetraLogic Birinapant UK Ltd.
    Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
  • Patent number: 9358222
    Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: June 7, 2016
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Bernard Thomas Golding, Christiane Riedinger, Roger John Griffin, Ian Robert Hardcastle, Eric Valeur, Anna Frances Watson, Martin Noble
  • Patent number: 9328168
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: May 3, 2016
    Assignee: LABRYS BIOLOGICS, INC.
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Patent number: 9198898
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: December 1, 2015
    Assignee: TIGERCAT PHARMA, INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • Patent number: 9187490
    Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: November 17, 2015
    Assignee: TetraLogic Birinapant UK Ltd.
    Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
  • Patent number: 9138423
    Abstract: The invention relates to the use of a compound of general formula (I), wherein R1 and R2 are independently H or C1-C6 alkyl, or R1 and R2 are bound to one another forming an optionally substituted fused benzene ring, R3 is H, C1-C6 alkyl or —CH2— CH(NH2)—COOH and R4 is H, C1-C6 alkyl, or R4 represents (II) or (III) in the preparation of a medicinal product for treating and/or preventing congenital erythropoietic porphyria (CEP).
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: September 22, 2015
    Assignee: Asociación Centro de Investigación Cooperativa en Biociencias—CIC Biogune
    Inventors: Oscar Millet Aguilar-Galindo, Ana Laín Torre
  • Patent number: 9119846
    Abstract: The invention relates to a pharmacologically active combination and a method of enhancing cognitive performance in a patient suffering from Alzheimer's disease comprising administering to said patient a cognitive performance-enhancing amount of melatonin or a melatonin agonist in a combination therapy with a nicotine receptor agonist.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: September 1, 2015
    Assignee: Neurim Pharmaceuticals (1991) Ltd.
    Inventors: Nava Zisapel, Moshe Laudon
  • Publication number: 20150148389
    Abstract: The invention is directed to methods of treating organ specific infections in a host organism by administering compounds that target host receptors and/or host cellular signaling molecules to prevent a pathogen from infecting the organ. For example, the administration of a compound to prevent a pathogen from crossing the blood-brain barrier to prevent a brain infection.
    Type: Application
    Filed: February 3, 2015
    Publication date: May 28, 2015
    Inventor: Kwang S. Kim
  • Publication number: 20150148359
    Abstract: Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 28, 2015
    Inventors: Uri Ben-David, Nissim Benvenisty, Payal Arora, Qing-Fen Gan, Ralph J. Garippa
  • Publication number: 20150141456
    Abstract: The present invention relates to tertiary amines of formula (I) for use in therapy, particularly for use in treating cardiovascular disorders. The compounds have been found to regulate phospholamban phosphorylation by interfering with the A-kinase anchor protein 18delta (AKAP18?) binding to the PKA substrate phospholamban. The compounds share a tri(alkylaryl/alkylheteroaryl) amine structure.
    Type: Application
    Filed: November 20, 2014
    Publication date: May 21, 2015
    Inventors: Jo Klaveness, Kjetil Tasken
  • Publication number: 20150142085
    Abstract: Pharmaceutical compositions and methods for treating and/or preventing age-related macular degeneration with melatonin analogues are provided.
    Type: Application
    Filed: July 21, 2014
    Publication date: May 21, 2015
    Inventors: David Baron, Keisuke Hirai, Yasushi Shintani, Osamu Uchikawa
  • Publication number: 20150141470
    Abstract: A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a MAPK pathway inhibitor, such as a RAF inhibitor, MEK inhibitor, or ERK inhibitor, and a GEF or HDAC inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a MAPK inhibitor, such as a RAF inhibitor, MEK inhibitor, or ERK inhibitor, and an effective amount of a GEF or HDAC inhibitor. A method of identifying targets that confers resistance to a MAPK pathway inhibitor is also provided.
    Type: Application
    Filed: May 8, 2013
    Publication date: May 21, 2015
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Levi A. Garraway, Cory M. Johannessen
  • Publication number: 20150140101
    Abstract: The present disclosure relates to solid oral compositions of silodosin or its pharmaceutically acceptable salt thereof. More particularly capsule compositions of silodosin with one or more pharmaceutically acceptable excipients and process for their preparation.
    Type: Application
    Filed: June 27, 2013
    Publication date: May 21, 2015
    Inventors: Bandi Parthasaradhi Reddy, Podili Khadgapathi, Goli Kamalakar Reddy
  • Patent number: 9034310
    Abstract: A method for pharmacological treatment of cancers and other diseases is presented which includes the novel combination of a statin (Hmg-CoA reductase inhibitor, such as lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, pravastatin, or newer agents), with an interferon (such as interferon alfa-2b or others) and also including concurrent administration of selenium and calcium. The method disclosed in this invention is useful because it can prove more effective than previously known therapies for certain diseases and because its use may be more tolerable, less disfiguring, and less expensive than other methods. The method here disclosed can be readily reproduced by any person skilled in the art of treating disease.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: May 19, 2015
    Inventor: Stephen B. Cantrell
  • Patent number: 9029413
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, and in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. Antiviral activity of enzyme inhibitors is demonstrated.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: May 12, 2015
    Assignee: The Trustees of Princeton University
    Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
  • Patent number: 9029379
    Abstract: Methods for treating Down syndrome and improving cognitive function of a patient with an intellectual disability are disclosed. 5-hydroxytryptamine sub-receptor six (5-HT6) receptor antagonists are provided for improving the cognition of a Down syndrome patient.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 12, 2015
    Assignee: The University of Utah Research Foundation
    Inventors: Julie Ruth Korenberg, Karen Sue Wilcox, Peter Jeffrey West, Raymond Pierre Kesner
  • Publication number: 20150126437
    Abstract: The disclosure provides compounds useful as insect repellents, compositions comprising such repellents, and methods of repelling an arthropod using such compounds and compositions. The disclosure further provides insect traps and method for identifying ligands and cognates for biological molecules.
    Type: Application
    Filed: October 17, 2012
    Publication date: May 7, 2015
    Applicant: The Regents of the University of California
    Inventors: Anandasankar Ray, Sean Michael Boyle
  • Publication number: 20150125518
    Abstract: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.
    Type: Application
    Filed: January 8, 2015
    Publication date: May 7, 2015
    Inventors: JOHN R. LAU, W. BLAIR GEHO